28,037 Shares in CRISPR Therapeutics AG $CRSP Purchased by Blue Jean Financial LLC

Blue Jean Financial LLC acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 28,037 shares of the company’s stock, valued at approximately $1,470,000.

Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada boosted its holdings in shares of CRISPR Therapeutics by 28.2% during the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock worth $4,856,000 after purchasing an additional 31,392 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth approximately $861,000. Woodline Partners LP boosted its holdings in shares of CRISPR Therapeutics by 34.3% during the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock worth $4,645,000 after purchasing an additional 34,883 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $237,000. Finally, Invesco Ltd. boosted its holdings in shares of CRISPR Therapeutics by 138.4% during the 2nd quarter. Invesco Ltd. now owns 66,648 shares of the company’s stock worth $3,242,000 after purchasing an additional 38,691 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CRSP. Wall Street Zen cut CRISPR Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Chardan Capital boosted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the stock an “equal weight” rating in a report on Thursday. UBS Group set a $80.00 target price on CRISPR Therapeutics in a report on Friday. Finally, Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $67.78.

CRISPR Therapeutics Stock Down 0.9%

CRSP stock opened at $49.80 on Friday. The firm has a market cap of $4.80 billion, a PE ratio of -8.01 and a beta of 1.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. The firm’s 50 day moving average price is $52.40 and its 200-day moving average price is $53.09. CRISPR Therapeutics AG has a one year low of $40.00 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -4.89 EPS for the current year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 10,020 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total transaction of $468,735.60. Following the sale, the chief executive officer owned 255,501 shares of the company’s stock, valued at approximately $11,952,336.78. The trade was a 3.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 3,182 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total transaction of $148,853.96. Following the sale, the general counsel directly owned 94,308 shares in the company, valued at approximately $4,411,728.24. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 33,937 shares of company stock valued at $1,646,126. 4.30% of the stock is currently owned by company insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.